Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis

Hongyu Li, Ran Wang, Nahum Méndez-Sánchez, Ying Peng, Xiaozhong Guo, Xingshun Qi, Hongyu Li, Ran Wang, Nahum Méndez-Sánchez, Ying Peng, Xiaozhong Guo, Xingshun Qi

Abstract

Introduction: Spider nevus and subcutaneous collateral vessel of the chest/abdominal wall are common in liver cirrhosis. This prospective study aimed to evaluate the impact of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall on the outcomes of cirrhotic patients.

Material and methods: We prospectively enrolled patients with a diagnosis of liver cirrhosis consecutively admitted to our department. We recorded the number and location of spider nevi and subcutaneous collateral vessels of the chest/abdominal wall. Clinical profiles and survival were compared according to the presence of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall. The study was registered (NCT02468479).

Results: Overall, 198 patients were enrolled between June 2015 and May 2016. The median follow-up duration was 350 days. The prevalence of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall was 47% and 29.8%, respectively. Patients with spider nevi had a significantly higher proportion of alcohol abuse (54.84% vs. 26.67%, p < 0.001). Both spider nevus and subcutaneous collateral vessel of the chest/abdominal wall were significantly associated with higher Child-Pugh (8.35 ±2.19 vs. 7.47 ±1.91, p = 0.005; 8.57 ±2.20 vs. 7.60 ±1.98, p = 0.002) and MELD scores (9.91 ±6.41 vs. 7.43 ±5.40, p = 0.008; 10.77 ±6.76 vs. 7.68 ±5.42, p = 0.003). The cumulative survival was not significantly different between patients with and without spider nevi of the chest/abdominal wall (p = 0.951). Patients with subcutaneous collateral vessels of the chest/abdominal wall had significantly worse cumulative survival (p = 0.018).

Conclusions: Presence of spider nevus and subcutaneous collateral vessel of the chest/abdominal wall indicated more severe liver dysfunction. Subcutaneous collateral vessel of the chest/abdominal wall should be a simple and important predictor for the overall survival of cirrhotic patients.

Keywords: Child-Pugh; complication; physical; prognosis; survival.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meir curve regarding the impact of spider nevus on cumulative survival of cirrhotic patients. A – Patients with vs. without spider nevus. B – Patients with 1–2 vs. 3–4 vs. ≥ 5 spider nevi of chest/abdominal wall
Figure 2
Figure 2
Kaplan-Meir curve regarding the impact of subcutaneous collateral vessel of abdominal/chest wall on cumulative survival of cirrhotic patients. A – Patients with versus without subcutaneous collateral vessel of abdominal/chest wall. B – Patients with subcutaneous collateral vessel of chest wall alone versus abdominal wall alone versus both abdominal and chest walls

References

    1. Khasnis A, Gokula RM. Spider nevus. J Postgrad Med. 2002;48:307–9.
    1. Vedamurthy M, Vedamurthy A. Spider nevi: a presenting feature of chronic liver disease. Indian J Dermatol Venereol Leprol. 2008;74:397–8.
    1. Satapathy SK, Bernstein D. Dermatologic disorders and the liver. Clin Liver Dis. 2011;15:165–82.
    1. Li CP, Lee FY, Hwang SJ, et al. Spider angiomas in patients with liver cirrhosis: role of alcoholism and impaired liver function. Scand J Gastroenterol. 1999;34:520–3.
    1. Du AS, Yang J, Lu S, Zeng JZ. [Facial skin lesions in male patients with liver cirrhosis: role of serum sex hormones and correlation with impaired liver function] Zhonghua Gan Zang Bing Za Zhi. 2013;21:354–8.
    1. Pirovino M, Linder R, Boss C, Kochli HP, Mahler F. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr. 1988;66:298–302.
    1. Li CP, Lee FY, Hwang SJ, et al. Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor. World J Gastroenterol. 2003;9:2832–5.
    1. Li CP, Lee FY, Hwang SJ, et al. Role of substance P in the pathogenesis of spider angiomas in patients with nonalcoholic liver cirrhosis. Am J Gastroenterol. 1999;94:502–7.
    1. Witte CL, Hicks T, Renert W, Witte MH, Butler C. Vascular spider: a cutaneous manifestation of hyperdynamic blood flow in hepatic cirrhosis. South Med J. 1975;68:246–8.
    1. Romagnuolo J, Jhangri GS, Jewell LD, Bain VG. Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol. 2001;96:3165–74.
    1. Romagnuolo J, Andrews CN, Bain VG, et al. Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model. Scand J Gastroenterol. 2005;40:1365–71.
    1. Niederau C, Lange S, Fruhauf M, Thiel A. Cutaneous signs of liver disease: value for prognosis of severe fibrosis and cirrhosis. Liver Int. 2008;28:659–66.
    1. Younis I, Sarwar S, Butt Z, Tanveer S, Qaadir A, Jadoon NA. Clinical characteristics, predictors, and survival among patients with hepatopulmonary syndrome. Ann Hepatol. 2015;14:354–60.
    1. Varghese J, Ilias-basha H, Dhanasekaran R, Singh S, Venkataraman J. Hepatopulmonary syndrome – past to present. Ann Hepatol. 2007;6:135–42.
    1. Groves AM, Dixon AK. Superficial collateral veins on abdominal CT: findings in cirrhosis and systemic venous obstruction. Br J Radiol. 2002;75:645–7.
    1. Yeh HC, Stancato-Pasik A, Ramos R, Rabinowitz JG. Paraumbilical venous collateral circulations: color Doppler ultrasound features. J Clin Ultrasound. 1996;24:359–66.
    1. Pagani JJ, Thomas JL, Bernardino ME. Computed tomographic manifestations of abdominal and pelvic venous collaterals. Radiology. 1982;142:415–9.
    1. Takano M, Imai Y, Nakazawa M, et al. A case of liver cirrhosis with bleeding from stomal varices successfully treated using balloon-occluded retrograde transvenous obliteration. Clin J Gastroenterol. 2016;9:145–9.
    1. Nakata M, Nakata W, Isoda N, Yoshizawa M, Sugimoto H. Percutaneous retrograde sclerotherapy for refractory bleeding of jejunal varices: direct injection via superficial epigastric vein. Cardiovasc Interv Radiol. 2012;35:203–6.
    1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51.
    1. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–66.
    1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21.
    1. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–8.
    1. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.
    1. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.
    1. Kamath PS, Kim WR. The model for end-stage liver disease (MELD) Hepatology. 2007;45:797–805.
    1. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099–108.
    1. Toshikuni N, Takuma Y, Tsutsumi M. Management of gastroesophageal varices in cirrhotic patients: current status and future directions. Ann Hepatol. 2016;15:314–25.
    1. Peng Y, Qi X, Dai J, Li H, Guo X. Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis. Int J Clin Exp Med. 2015;8:751–7.
    1. Zou D, Qi X, Zhu C, et al. Albumin-bilirubin score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis: a retrospective study. Turk J Gastroenterol. 2016;27:180–6.
    1. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35.
    1. Qi X, Ye C, Guo X. Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope. Arch Med Sci. 2017;13:496–9.
    1. Krok KL, Wagennar RR, Kantsevoy SV, Thuluvath PJ. Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis. Arch Med Sci. 2016;12:365–71.
    1. Deng H, Qi X, Guo X. Diagnostic accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex scores in predicting the presence of esophageal varices in liver cirrhosis: a systematic review and meta-analysis. Medicine (Baltimore) 2015;94:e1795.
    1. Deng H, Qi X, Peng Y, et al. Diagnostic accuracy of APRI, AAR, FIB-4, FI, and King scores for diagnosis of esophageal varices in liver cirrhosis: a retrospective study. Med Sci Monit. 2015;21:3961–77.
    1. Alderson MR. Spider naevi: their incidence in healthy schoolchildren. Arch Dis Child. 1963;38:286–8.
    1. Finn SM, Rowland M, Lawlor F, et al. The significance of cutaneous spider naevi in children. Arch Dis Child. 2006;91:604–5.
    1. Wenzl JE, Burgert EO., Jr The spider nevus in infancy and childhood. Pediatrics. 1964;33:227–32.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться